Related Experiment Video

Updated: May 14, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Role of epidermal growth factor receptor inhibitors in epidermal growth factor receptor wild-type non-small-cell lung

Scott A Laurie1, Glenwood D Goss

  • 1Division of Medical Oncology, Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, Ontario, Canada. laurie@toh.on.ca

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|February 13, 2013
PubMed

Insights

Most advanced non-small-cell lung cancer (NSCLC) patients lack EGFR mutations. Current biomarkers don't predict benefit for these wild-type NSCLC patients receiving EGFR inhibitors, necessitating further research.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • The majority of advanced non-small-cell lung cancer (NSCLC) patients worldwide do not possess activating mutations in the epidermal growth factor receptor (EGFR) tyrosine kinase domain.
  • These wild-type EGFR patients represent a substantial group receiving EGFR pathway inhibitors, with some showing modest clinical benefit.

Purpose of the Study:

  • To address the lack of predictive biomarkers for identifying wild-type EGFR non-small-cell lung cancer patients who will not benefit from EGFR tyrosine kinase inhibitors.
  • To highlight ongoing investigations into strategies for enhancing the efficacy of these inhibitors in the wild-type NSCLC population.

Main Methods:

  • Review of existing clinical trial data regarding EGFR tyrosine kinase inhibitor efficacy in advanced NSCLC.
  • Analysis of biomarker data for predicting response and progression-free survival in EGFR wild-type patients.
  • Identification of current research directions for improving treatment outcomes.

Main Results:

  • Activating EGFR mutations predict a higher likelihood of response and longer progression-free survival with EGFR tyrosine kinase inhibitors.
  • Currently, no reliable biomarkers consistently predict lack of benefit in EGFR wild-type NSCLC patients.
  • Some EGFR wild-type patients demonstrate a modest benefit from these targeted therapies.

Conclusions:

  • Predictive biomarkers for EGFR tyrosine kinase inhibitor benefit in wild-type NSCLC are critically needed.
  • Further research is essential to develop strategies that improve the efficacy of EGFR inhibitors in this patient subgroup.
  • Understanding treatment response in EGFR wild-type NSCLC is crucial for optimizing patient care.

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal01:22

Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal

Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...